Bharat Enters Chikungunya Fray As Vaccine Moves Into Trials

Indian vaccine developer Bharat Biotech has moved a candidate vaccine for chikungunya into Phase I trials, joining over a dozen firms worldwide hoping to commercialize the first vaccine to halt transmission of the painful mosquito-borne illness, which is spreading globally.

Close-up of a mosquito sucking blood

Privately held Indian vaccine maker Bharat Biotech International Ltd., which already has two candidates in the race to create the world’s first vaccine to protect against the Zika virus, is now hoping to develop a vaccine to prevent the debilitating illness chikungunya.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from India

More from Focus On Asia